MMS Stock Analysis — Maximus Inc.
Sector: Business Services
AI Verdict
MMS is cheap for the growth you're getting, but the market is skeptical that a 49.0% EPS jump is sustainable given last year's -1.4% revenue decline—if the moat holds and contracts flow, this is deep value, but execution risk is high.
Competitive Moat
Maximus operates large-scale government health and human services contracts, where incumbency and regulatory expertise create high switching costs for agencies. Its defensibility comes from deep integration with government processes and compliance requirements that make displacement difficult.
Summary
A 49.0% forward EPS growth forecast and a 6.3x forward P/E make MMS a rare deep-value outlier in business services.
Where It Stands
MMS trades at just 6.3x next year's earnings while analysts expect 49.0% EPS growth, far below the sector median P/E of 20x and despite a -1.4% revenue dip last year.
Key Metrics
- Trailing P/E: 9.4x
- Forward P/E: 6.3x
- PEG Ratio: 0.19
- Earnings Growth: +0.5%
- Revenue Growth: -0.0%
- Dividend Yield: 0.02%
- 52-Week High: $100.00
- 52-Week Low: $52.73
Analyst Consensus
5 Buy · 1 Hold · 0 Sell (6 analysts)
Bull Case
With a forward P/E of 6.3x and nearly 50% expected EPS growth, you're paying a bargain price for a turnaround if execution matches forecasts.
Bear Case
If the 49.0% EPS growth doesn't materialize, even a modest re-rating to the trailing P/E of 9.4x would mean little upside and could see the stock languish.
Catalyst to Watch
Watch upcoming contract wins or renewals—securing new government deals would confirm the growth outlook and support the low valuation.